Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

32.26 -0.73 (-2.23%)
Streaming Delayed Price Updated: 1:24 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MBX Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know ↗
Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 14, 2025 ↗
 
Via Benzinga
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
A Glimpse of MBX Biosciences's Earnings Potential ↗
 
Via Benzinga
News headline image
Which stocks have an unusual volume on Thursday? ↗
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the... 
Via Benzinga
Topics Stocks
News headline image
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants. 
Via Benzinga
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
On Tuesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
Stock Market Today: Nasdaq Futures Rise, S&P 500 Slips Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focus ↗
U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
News headline image
AutoZone, Micron Technology And 3 Stocks To Watch Heading Into Tuesday ↗
U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosciences public offering. 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-09-22: top gainers and losers in today's session. ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Gold Gains Over 1%; Quantum Computing Shares Plunge ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In August ↗
 
Via Benzinga
Topics Economy Stocks
News headline image
MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise ↗
The company is working on an experimental treatment for a thyroid disease. 
Via Investor's Business Daily
News headline image
Monday's pre-market session: top gainers and losers ↗
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study ↗
MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy, safety profile, and plans for Phase 3 in 2026. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Friday? ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Mbx Biosciences (MBX) Q2 Loss Widens 22% ↗
Via The Motley Fool
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.